California is currently home to 5616 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Screening Emotions in Adolescents at the Hospital for mTBI
NCT06370520
Recruiting
The goal of this observational study is to develop and validate a clinical tool to predict which adolescents aged 11 to less than 18 years of age with mild traumatic brain injury (mTBI) are at an increased risk for developing significant new or worsening mental health conditions. The main aims the study wish to answer are: * Does the adolescent have new or worsening depression or anxiety defined as a change from their previous medical history using self-reported questionnaires at either one or... Read More
Gender:
ALL
Ages:
Between 11 years and 17 years
Trial Updated:
09/19/2024
Locations: University of California, Davis Medical Center, Sacramento, California
Conditions: Brain Injury Traumatic Mild, Brain Injuries, Brain Injuries, Acute, Head Injury With Intracranial Hemorrhage, Head Injury Trauma, Brain Injury Traumatic Focal With Loss of Consciousness, Skull Fractures, Diffuse Axonal Injury, Intracranial Hemorrhages, Head Injury
Register for Updates
Effects of PFC tDCS on Cognitive Control, Attention Lapses and Coordinated Neural Activity in the Theta and Alpha Bands
NCT04885322
Recruiting
The purpose of this study is to better understand the neural correlates of higher-order cognition, both in the healthy brain and in schizophrenia, and to determine how these mechanisms are modulated by transcranial direct current stimulation (tDCS) at frontal and occipital scalp sites. Testing the effects of tDCS at these scalp sites on cognitive task performance will help us understand the roles of the brain regions corresponding to these sites during higher-order cognitive processing (language... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
09/19/2024
Locations: Imaging Research Center, Sacramento, California
Conditions: Healthy
Register for Updates
Leveraging Artificial Intelligence and Multi-Omics Data to Predict Opioid Addiction
NCT06540105
Recruiting
The primary goal of this proposal is to validate a novel genomic and microbiome predictive model that may be used to assess a person's risk of developing opioid use disorder (OUD). The following will be tested: (1) MODUS (Measuring risk for Opioid use Disorder Using SNPs), which is a genomic panel consisting of a set number of proven single nucleotide polymorphisms (SNP) that utilizes machine learning to determine an individual's risk; and (2) MICROUD (MICRObiome for Opioid Use Disorder), which... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: University of California, San Diego, La Jolla, California
Conditions: Opioid Use Disorder, Addiction, Opioid
Register for Updates
Neurophysiologic Biomarkers for Cognitive Rehabilitation
NCT05945602
Recruiting
Cognitive symptoms of schizophrenia interfere with daily life-from managing self-care, to more complex tasks like taking medications and living independently. Unfortunately, these cognitive symptoms are not corrected by 'standard of care' treatments (antipsychotic medications), although some schizophrenia patients may experience modest clinical and cognitive benefits from cognitive remediation. To enhance the clinical impact of cognitive remediation and other rehabilitative interventions for Vet... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/18/2024
Locations: VA San Diego Healthcare System, San Diego, CA, San Diego, California
Conditions: Schizophrenia Spectrum Disorders
Register for Updates
Rheumatoid Arthritis Shared Decision Making
NCT05530694
Recruiting
Shared decision making is the first overarching principle for the treat to target guidelines for rheumatoid arthritis (RA) and has been proposed as a potential mechanism to reduce health disparities, however there is little evidence to inform effective ways to implement this practice in the care of Veterans with RA. The purpose of this project is to evaluate the effectiveness of a multi-component shared decision making intervention on RA disease activity, adherence to RA medications and patient... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: San Francisco VA Medical Center, San Francisco, CA, San Francisco, California
Conditions: Rheumatoid Arthritis
Register for Updates
Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease
NCT04774536
Recruiting
This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells (known as CRISPR_SCD001 Drug Product).
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
09/18/2024
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Sickle Cell Disease
Register for Updates
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
NCT03587844
Recruiting
The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: Stanford University Medical Center, Stanford, California
Conditions: Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
Register for Updates
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: UCSF Benioff Children's Hospital Oakland-, Oakland, California
Conditions: Neuroblastoma
Register for Updates
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
NCT06554795
Recruiting
A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: Site USA08-0, Newport Beach, California
Conditions: Solid Tumor, Adult
Register for Updates
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed or Refractory Grade 1-3a Follicular Lymphoma
NCT06453044
Recruiting
This phase II trial tests how well mosunetuzumab and polatuzumab vedotin works in treating patients with grade 1-3a follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B po... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma
Register for Updates
Evaluation of SINGLE PORT (SP) Robotic Technology in Colorectal Surgery
NCT05321134
Recruiting
Currently a multiport robotic surgery platform (Intuitive Xi) is widely available and used for colorectal surgery indications. A Single port platform (Intuitive SP) is FDA approved for Head and Neck and Urology but has not been widely used in colorectal surgery. This study seeks to evaluate the safe and effective use of the SP platform for colorectal surgery indications.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: UC Davis Medical Center, Sacramento, California
Conditions: Colo-rectal Cancer, Rectal Prolapse, Colostomy Stoma, Colorectal Disorders
Register for Updates
Brentuximab Vedotin and Nivolumab for the Treatment of Patients with Relapsed/refractory Classical Hodgkin Lymphoma
NCT04561206
Recruiting
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune sys... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Relapsed Classic Hodgkin Lymphoma
Register for Updates